Navigation Links
Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia

ossible for the sequences to match so closely."

The ability to easily compare plants and bacteria is the result of genome sequencing, which has decoded the complete genetic blueprint for entire species. "This would not have been possible 10 years ago," said Leustek. "But now we have access to more that 500 different genomes in a data base. After having identified a gene in plants, I can quickly identify the homologous gene from any bacteria in the database. As a plant biologist I wouldn't have ever imagined that I would be working with Chlamydia. Yet, with the help of genomics I found myself working with a collaborator and publishing a paper in that area."

Their experiments revealed that in addition to sharing genome sequences, Chlamydia and plants share similar functions as well. Furthermore, they found that the pathway used by plants to produce lysine is probably used by Chlamydia to synthesize a chemical found in bacterial cell walls. It is the synthesis of cell walls that is inhibited by penicillin. This discovery points to the likelihood that, if researchers could find an inhibitor for L,L-diaminopimelate aminotransferase they would have a new antibiotic that would target Chlamydia.

Chlamydia trachomatis is a bacteria that is responsible for a common STD. If untreated, Chlamydia infections can damage a woman's reproductive organs and lead to infertility. An estimated 2.8 million men and women in the U.S. are infected with chlamydia each year. Chlamydia can be easily treated and cured with antibiotics. However, bacteria often develop resistance to antibiotics, meaning that new ones must be continually discovered. Moreover, an inhibitor to L,L-diaminopimelate aminotransferase would be very specific for Chlamydia since this enzyme has not been found in any bacteria that live with humans.

So the hunt for a new antibiotic is on. Leustek is going to start screening for chemicals that block the enzyme. He is also using the res
'"/>

Source:Rutgers, the State University of New Jersey


Page: 1 2 3

Related biology news :

1. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
2. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
3. Men Estimate Mens Risks Of Common Disorders Higher Than Women Do, And Vice Versa
4. Use of Antibiotics for Acne May Increase Risk of Common Illness
5. Common viruses may cause cancer
6. Common alternative treatment for liver disease is found to be ineffective
7. Common molecular signature identified in solid tumors
8. Common bacteria pirate natural mechanism to get inside cells
9. Commonly used antidepressants may also affect human immune system
10. Common practices at petting zoos put visitors at risk
11. Common enzyme is a key player in DNA repair
Post Your Comments:
(Date:7/11/2014)... Canyon fire started near the City of Entiat on ... resources, the fire quickly grew to over 1,000 acres ... the fire is under investigation by the Washington Department ... with existing local resources in developing fire control strategies ... (USFS), Washington State Department of Natural Resources, (WA DNR), ...
(Date:7/11/2014)... of Chicago is creating a new professorship in ... University,s Institute for Molecular Engineering and the Marine ... from the Millicent and Eugene Bell Foundation., The ... within the Institute for Molecular Engineering. That endowed ... at the MBL,s Eugene Bell Center for Regenerative ...
(Date:7/11/2014)... have set a "mouse TRAP" to capture the early ... study published in the Journal of Clinical Investigation ... called TRAP to extract cellular and genetic information from ... at the Rockefeller Institute for Medical Research in 2008, ... machinery, or ribosomes, of the cell type of interest. ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2
... HONOLULU While the iconic Haleakalā silversword plant made a ... a period of substantial climate-related decline. New research published this ... the silversword in its native habitat. Known for its ... single reproductive event at the end of its life, at ...
... structural similarity to asbestos, have been alleviated following research ... In a new study, published today in ... that the asbestos-like reactivity and pathogenicity reported for long, ... is modified and their effective length is reduced as ...
... DENVER Recent studies have demonstrated that molecular-targeted agents, ... inhibitors (TKI), may prolong survival of selected patients based ... EGFR gene is known as a predictive marker for ... EGFR mutations are prognostic factors for non-small cell lung ...
Cached Biology News:Global warming may have severe consequences for rare Haleakalā silverswords 2Chemistry resolves toxic concerns about carbon nanotubes 2EGFR mutation not prognostic factor in non-small cell lung cancer 2
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... DUBLIN, August 3, 2010 , - Proposed recommended cash acquisition ... a fully diluted equity purchase price of, EUR428 ... date, Movetis held EUR100 million in cash; based on this ... be EUR328 million, - Strong strategic fit with Shire,s growing ...
... ,, ROCKVILLE, Md. , Aug. 2 Vanda Pharmaceuticals Inc. ... the development and commercialization of products for central nervous system disorders, today announced ... August 5, 2010 , before the market opens. A full text copy of ... , , ...
... , CHICAGO and HOBOKEN, N.J. , Aug. 2 ... of the Octapharma 25th Anniversary Grants Program is the Rush ... Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies ... , , ...
Cached Biology Technology:Shire Proposes to Expand Specialist Gastrointestinal Portfolio 2Shire Proposes to Expand Specialist Gastrointestinal Portfolio 3Shire Proposes to Expand Specialist Gastrointestinal Portfolio 4Shire Proposes to Expand Specialist Gastrointestinal Portfolio 5Shire Proposes to Expand Specialist Gastrointestinal Portfolio 6Shire Proposes to Expand Specialist Gastrointestinal Portfolio 7Shire Proposes to Expand Specialist Gastrointestinal Portfolio 8Shire Proposes to Expand Specialist Gastrointestinal Portfolio 9Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide derived ... C-terminus of Human MSY2/YBOX2. (Note: ... (Peptide available as ...
...
Request Info...
Biology Products: